Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP803059.RAXxbi5DLDcQiRwQj4p3S_8wTtgnQunUsu21BTW7uvifU130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP803059.RAXxbi5DLDcQiRwQj4p3S_8wTtgnQunUsu21BTW7uvifU130_assertion type Assertion NP803059.RAXxbi5DLDcQiRwQj4p3S_8wTtgnQunUsu21BTW7uvifU130_head.
- NP803059.RAXxbi5DLDcQiRwQj4p3S_8wTtgnQunUsu21BTW7uvifU130_assertion description "[Amplified genes were noted in 37% of gastric/esophageal tumors, including in therapeutically targetable kinases such as ERBB2, FGFR1, FGFR2, EGFR, and MET, suggesting the potential use of genomic amplifications as biomarkers to guide therapy of gastric and esophageal cancers where targeted therapeutics have been less developed compared with colorectal cancers.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP803059.RAXxbi5DLDcQiRwQj4p3S_8wTtgnQunUsu21BTW7uvifU130_provenance.
- NP803059.RAXxbi5DLDcQiRwQj4p3S_8wTtgnQunUsu21BTW7uvifU130_assertion evidence source_evidence_literature NP803059.RAXxbi5DLDcQiRwQj4p3S_8wTtgnQunUsu21BTW7uvifU130_provenance.
- NP803059.RAXxbi5DLDcQiRwQj4p3S_8wTtgnQunUsu21BTW7uvifU130_assertion SIO_000772 22751462 NP803059.RAXxbi5DLDcQiRwQj4p3S_8wTtgnQunUsu21BTW7uvifU130_provenance.
- NP803059.RAXxbi5DLDcQiRwQj4p3S_8wTtgnQunUsu21BTW7uvifU130_assertion wasDerivedFrom befree-20150227 NP803059.RAXxbi5DLDcQiRwQj4p3S_8wTtgnQunUsu21BTW7uvifU130_provenance.
- NP803059.RAXxbi5DLDcQiRwQj4p3S_8wTtgnQunUsu21BTW7uvifU130_assertion wasGeneratedBy ECO_0000203 NP803059.RAXxbi5DLDcQiRwQj4p3S_8wTtgnQunUsu21BTW7uvifU130_provenance.